Greek Hospitals' Pharma Debt Settlement Underway

18 May 1997

In Greece, the process for settling hospital debts to suppliers ofpharmaceuticals and other products has now begun (Marketletter February 3). The debt to the manufacturers now totals 197 billion drachmas ($722.3 million), to be repaid by government bonds of two, three and four-year duration.

At a meeting last week with officials of the Ministry of Health and the National Bank, Paul Giannacopoulos, president of the Association of Representative of Pharmaceutical Products and Specialties, was assured that the issuing of government bonds for payment of the debts would begin within three weeks at the latest. The National Bank was selected for the debt settlement by bonds. 5% of the the total will also be paid in cash, as quickly as possible, by the hospitals.

Mr Giannacopoulos notes that the huge public debts to the drug and medical products suppliers has caused serious problems not only to the industry but also to the hospitals. A recent tender by the Ministry of Development for the supply of pacemakers for 18 hospitals, worth around 3.5 billion drachmas ($12.8 million), will have to be repeated, as not a single application was received from any of the 20 suppliers of these products to the Greek market.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight